Replies to post #94955 on Biotech Values

[skitahoe]

Dew,

There are many other companies and drugs that you've put down over the years, as I understand it, you were death on DNDN and Provenge, how do you feel about that decision today.

Unfortunately, I never bought into more then a few options, and my timing was wrong there, but I never doubted that in time they would gain approval. I wasn't certain this would be the time, but I'm happy the FDA is finally not obstructing drugs from companies that aren't yet paying them. It won't be long before DNDN will be.

What do you say to those who honestly follow you and who were talked out of their investments in DNDN by your wisdom.

I may be wrong about my choices, but I always recommend that others look and judge for themselves. I don't care if a stock is 70 cents or $70 when I look at it, but I do ask if both have 10 banger potential, how about 100 banger. Today I don't place DNDN at the point where it will be more than a 2 banger from where it is today, and lucky if it does that, but does it have the potential to do so, most certainly.

Whether you like it or not, I'll be saying more about it later.

Gary

[bladerunner1717]

re: GNVC


GenVec Receives NASDAQ Notice of Minimum Bid Price Non-Compliance



GAITHERSBURG, Md., May 13 /PRNewswire-FirstCall/ -- On May 12, 2010 GenVec, Inc. (Nasdaq: GNVC) received a notice from The NASDAQ Stock Market stating that the minimum bid price of the Company's common stock was below $1.00 per share for 30 consecutive business days and that the Company was therefore not in compliance with the minimum bid price requirement for continued listing set forth in Marketplace Rule 5450. The notification letter has no effect at this time on the listing of the Company's common stock on The NASDAQ Global Market. GenVec's common stock will continue to trade on The NASDAQ Global Market under the symbol GNVC.



The notification letter states that GenVec will be afforded 180 calendar days, or until November 8, 2010, to regain compliance with the minimum closing bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for at least ten consecutive business days during the 180 calendar day grace period. NASDAQ may, in its discretion, require the Company's common stock to maintain a bid price of at least $1.00 per share for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.



If the Company does not regain compliance by November 8, 2010, NASDAQ will provide written notification to the Company that the Company's common stock will be delisted. At that time, the Company may appeal NASDAQ's delisting determination to a Nasdaq Listing Qualifications Panel. Alternatively, the Company could apply to transfer its common stock to The NASDAQ Capital Market if it satisfies all of the requirements, other than the minimum bid price requirement, for initial listing on The NASDAQ Capital Market set forth in Marketplace Rule 5505. If the Company were to elect to apply for such transfer and if it satisfies the applicable requirements and its application is approved, the Company would have an additional 180 days to regain compliance with the minimum bid price rule while listed on The NASDAQ Capital Market.



The Company intends to actively monitor the bid price for its common stock between now and November 8, 2010, and will consider available options to resolve the deficiency and regain compliance with the NASDAQ minimum bid price requirement.



Bladerunner